KTTAW
BASIC MATERIALSPasithea Therapeutics Corp. Warrant
$0.01-0.00 (-1.23%)PRE
Live · NASDAQ · May 13, Close
AI Insight
What's Moving KTTAW Today?
No stock-specific AI insight has been generated for KTTAW yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.01$0.12
$0.01
Fundamentals
Market Cap—
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE-0.6%
Profit Margin—
Debt / Equity—
Trading
Volume—
Avg Volume (10D)—
Shares Outstanding—
KTTAW News
15 articles- Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical OfficerYahoo Finance·May 4, 2026
- Is Pasithea Therapeutics (NASDAQ:KTTA) In A Good Position To Deliver On Growth Plans?Yahoo Finance·May 3, 2026
- Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1)Yahoo Finance·Apr 20, 2026
- Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant MorbidityYahoo Finance·Apr 1, 2026
- Pasithea Therapeutics Announces Activation of Clinical Trial Site at University of Alabama at Birmingham for Ongoing Phase 1/1b Trial of PAS-004 in Adult NF1 PatientsYahoo Finance·Nov 4, 2025
- Pasithea Therapeutics Announces Activation of Clinical Trial Sites in South Korea for Phase 1/1b Trial of PAS-004 in Adult NF1 PatientsYahoo Finance·Sep 16, 2025
- Pasithea Therapeutics Announces Enrollment of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for its Ongoing Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 PatientsYahoo Finance·Sep 8, 2025
- Pasithea Therapeutics Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment ConferenceYahoo Finance·Aug 29, 2025
- Pasithea Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceYahoo Finance·Aug 28, 2025
- Pasithea Therapeutics Completes Enrollment and Initial Dosing of First Cohort from its Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 PatientsYahoo Finance·Jul 31, 2025
- Pasithea Therapeutics Appoints Expert in ETS2-driven Inflammatory Disease to Scientific Advisory BoardYahoo Finance·Jun 11, 2025
- Pasithea Therapeutics Presents Updated Interim Data from Ongoing Phase 1 Study of PAS-004 at the ASCO Annual Meeting 2025Yahoo Finance·Jun 2, 2025
- Pasithea Therapeutics Announces Preclinical Data that Shows PAS-004 Inhibits ETS2 Signaling, a Key Driver of Inflammation in IBD and Other Large Addressable Market DiseasesYahoo Finance·May 20, 2025
- Pasithea to commence Phase I/Ib trial of neurofibromatosis type 1 therapyClinicaltrialsarena·May 15, 2025
- Pasithea Therapeutics Announces Initiation of Phase 1/1B Study of PAS-004 in Adult NF1 Patients and Activation of First Clinical Trial SiteYahoo Finance·May 14, 2025
All 15 articles loaded
Price Data
Open$0.00
Previous Close$0.01
Day High$0.00
Day Low$0.00
52 Week High$0.12
52 Week Low$0.01
52-Week Range
$0.01$0.12
$0.01
Fundamentals
Market Cap—
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE-0.6%
Profit Margin—
Debt / Equity—
Trading
Volume—
Avg Volume (10D)—
Shares Outstanding—
About Pasithea Therapeutics Corp. Warrant
Pasithea Therapeutics Corp. The company is headquartered in Miami Beach, Florida.
BASIC MATERIALSPHARMACEUTICAL PREPARATIONS
Company Details
Security TypeWarrant
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICPHARMACEUTICAL PREPARATIONS
CIK—
Composite FIGI—
Share Class FIGI—